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Background: The current standard of care for salvage treatment of glioblastoma multi-
forme (GBM) is gross total resection and adjuvant chemoradiation for operable patients.
Limited evidence exists to suggest that any particular treatmentmodality improves survival
for recurrent GBM, especially if inoperable. We report our experience with fractionated
stereotactic radiotherapy (fSRT) with and without chemo/immunotherapy, identifying
prognostic factors associated with prolonged survival.
Methods: From 2007 to 2014, 19 patients between 29 and 78 years old (median 55)
with recurrent GBM following resection and chemoradiation for their initial tumor, received
18–35Gy (median 25) in three to five fractions via CyberKnife fSRT. Clinical target volume
(CTV) ranged from 0.9 to 152 cc. Sixteen patients received adjuvant systemic therapy
with bevacizumab (BEV), temozolomide (TMZ), anti-epidermal growth factor receptor
(125)I-mAb 425, or some combination thereof.
Results: The median overall survival (OS) from date of recurrence was 8months (2.5–61)
and 5.3months (0.6–58) from the end of fSRT. The OS at 6 and 12months was 47
and 32%, respectively. Three of 19 patients were alive at the time of this review at
20, 49, and 58months from completion of fSRT. Hazard ratios for survival indicated
that patients with a frontal lobe tumor, adjuvant treatment with either BEV or TMZ,
time to first recurrence >16months, CTV <36 cc, recursive partitioning analysis <5,
and Eastern Cooperative Oncology Group performance status <2 were all associated
with improved survival (P<0.05). There was no evidence of radionecrosis for any
patient.
Conclusion: Radiation Therapy Oncology Group (RTOG) 1205 will establish the role
of re-irradiation for recurrent GBM, however our study suggests that CyberKnife with
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chemotherapy can be safely delivered, and is most effective in patients with smaller frontal
lobe tumors, good performance status, or long interval from diagnosis.
Keywords: recurrent glioblastoma, glioblastoma radiosurgery, glioblastoma stereotactic, salvage stereotactic,
glioblastoma multiforme
Introduction
The most common and aggressive primary brain malignancy in
adults, glioblastoma multiforme (GBM), recurs in over 75% of
patients with amedian time interval of 8months (1–3). Stupp et al.
established radiotherapy with concurrent temozolomide (TMZ)
as the initial treatment paradigm for GBM, however, the most
appropriate salvage therapy was not determined (3). Thus far,
limited evidence exists to suggest that any particular treatment
modality improves survival with recurrence (4). The current stan-
dard of care for GBM recurrence is gross total resection fol-
lowed by adjuvant chemoradiation, but only a select number of
patients are healthy enough to endure surgery (5). Retrospective
data on surgical resection of recurrent GBM suggest a pallia-
tive and local control benefit, without prolonged survival (2, 6,
7). Chemotherapy offers a modest survival benefit for recurrent
GBM that improves as newer agents are employed, such as TMZ.
While TMZ has proven to be an effective salvage therapy, the
alkylating agent’s greatest contribution to survival has been as a
radiosensitizer (8–12). Recently, the vascular endothelial growth
factor (VEGF) inhibitor, bevacizumab (BEV) has also emerged
as an effective systemic treatment for recurrent GBM, replacing
TMZ as the standard of care (13–16). However, the combination
of BEV with chemotherapy in phase II trials revealed increased
toxicity without greater efficacy (17–19). Among the emerging
immunologic therapies, (125)I labeled anti-epidermal growth fac-
tor receptor (EGFR) 425 murine monoclonal antibody (I-mAb
425) produced promising results in a large prospective single-arm
study for newly diagnosed GBMs, but the data for its role in recur-
rence are inconclusive (20). The role of radiotherapy in recurrent
GBM treatment is not clearly defined, although retrospective data
suggest that there is an improvement in tumor control without a
great impact on survival (21).
Because of its utility in the non-surgical setting and its versatil-
ity as either definitive or adjuvant treatment, radiation is the most
consistently used modality for GBM. Historically, radiotherapy
has been used to treat GBMs in the form of conventional external
beam radiation, brachytherapy, stereotactic radiosurgery (SRS,
single fraction radiation), and fractionated stereotactic radiation
therapy (fSRT, two to five fractions of radiation). Phase III trials
have shown no benefit to boosting external beam radiation with
brachytherapy (22, 23). An additional phase III study failed to
demonstrate that SRS boost followed by external beam radiation
could deliver a superior outcome compared to standard fraction-
ated external beam radiation alone (24). SRS/fSRT, however, has
proven to be non-inferior to conventional radiation and given its
convenience and ability to deliver a highly conformal dose with
precision, it is emerging as a favorable treatment for recurrent
brain tumors (4). Among the technology equipped to deliver SRS,
CyberKnife (Accuray Inc., Sunnyvale, CA, USA) is a system in
which a linear accelerator mounted on a robotic armmoves in any
direction and angle to align with its target and deliver hundreds
of radiation beamlets at higher doses and tighter margins than
conventional radiation (25). The precision of such technology is
well suited for neuro-oncologic treatment, even in the case of
re-irradiation, as described in the literature (4).
Several retrospective studies reported survival results for recur-
rent GBM treated with either SRS or fSRT, with median survival
time from re-irradiation between 5.7 to 14.3months (median
10months) (26–38). In a prospective cohort of 31 patients with
recurrent GBM, Greenspoon et al. described a median overall
survival (OS) of 9months in patients receiving 25–35Gy in five
fractions and concurrent TMZ (39). We aim to contribute to
the survival outcomes of patients with recurrent GBM treated by
CyberKnife fSRT and either surgery, chemotherapy, immunother-
apy, or some combination thereof. We also want to examine
possible pretreatment or treatment factors significant for survival,
elaborating on the three patients still alive at the time of this
review.
Materials and Methods
From June 2007 to January 2014, 19 patients with biopsy-proven
recurrent GBM were treated at the Philadelphia CyberKnife Cen-
ter and retrospectively reviewed with Institutional Review Board
approval. Inclusion in the study required radiographic evidence
of remission with computed tomography (CT) or magnetic res-
onance image (MRI) following initial treatment, as well as radio-
graphic evidence of recurrence, with or without secondary biopsy.
Initial treatment with surgery, radiation, or systemic therapy
in any combination was considered. Treatment of recurrence
had to include fSRT with CyberKnife, with or without surgery,
chemotherapy, or immunotherapy.
Contrast-enhanced CT images with 1.25mm thickness were
used to generate individualized treatment plans and to derive dig-
itally reconstructed radiographs to facilitate alignment for stereo-
tactic treatment. T1- and T2-weightedMRI with gadoliniumwere
three-dimensionally fused with the planning CT and transferred
to Multiplan software to delineate target volumes and critical
structures. Gross tumor volume (GTV) was the same as clinical
target volume (CTV) which included the entirety of an enhancing
lesion representing tumor or the surgical cavity if the patient had
a reoperation. The planning target volume (PTV) included the
CTV with 0–2mm margins (median 1.25mm). The dose was
prescribed to the 65–77% isodose line (median 73%) at a dose of
18–35Gy (median 25Gy) in three to five fractions. The biological
equivalent dose (BED) ranged from 28 to 60Gy (median 37.5Gy),
using an α/β of 10. During treatment and planning CT, the
patient wore a custom-made immobilization mask. Orthogonal
X-rays of the skull were aligned with radiographs reconstructed
from the planning CTs and measurements necessary to bring the
images into alignment were conveyed to the treatment table for
proper adjustment. Skull tracking was performed every three to
five beams throughout treatment delivery for optimal position. A
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linear accelerator mounted on a robotic arm delivered between
103 and 307 (median 150) non-isocentric beams to irradiate a
single target stereotactically.
Patients were typically seen 1–3months after salvage treatment.
A CT, PET, or MRI was ordered at least every 3months follow-
ing salvage treatment. Recurrence was defined as an enlarging
enhancing mass by MRI or PET/CT. Univariate Cox regression
models were used to estimate hazard ratios of prognostic factors
and Kaplan–Meier curves were used to illustrate OS. Cox and log-
rank tests for statistical significance were used where appropriate.
Results
Patients
Thirteen males and six females, median age 56 (29–79) had histo-
logically proven primary GBMs between the years 1999 and 2012,
with radiographic evidence of recurrence. One of the patients
had a primary grade 2 astrocytoma, which recurred as a GBM
and resected at time of recurrence. All but two primary tumors
were resected, and all patients received conventional radiation at
54–60Gy in 28–32 fractions, as well as TMZ-based chemotherapy
for their initial treatment. The median time to recurrence was
16months (2–122), and median Karnofsky performance status
(KPS) at recurrencewas 80 (40–100).Nine patients had a recursive
partitioning analysis (RPA)<5, another nine had an RPA equal to
5 with one patient a score of 6. Sizes of recurrent lesions ranged
from 0.9 to 152 cc (mean 36 39.9 cc). Upon recurrence, one
lesion was completely excised and three were subtotally resected,
two of which had gliadel wafers implanted. BEV-based salvage
therapy was employed with 4 patients prior to CyberKnife treat-
ment, and 12 received systemic therapy with either BEV (6), TMZ
(4), or both (2) after re-irradiation. Three patients received I-
425 mAb injections for their initial GBM, and three received the
therapy after fSRT for recurrence, though it was never used as
an initial salvage treatment. Each patient was re-irradiated with
CyberKnife fSRT. One patient received a second fSRT treatment
of 20Gy in five fractions at a different site (right parietal then
right frontal), and another patient received 25Gy in five fractions
to the same site in the left temporal lobe. A third patient was re-
irradiated for multiple recurrences to 20Gy in five fractions at the
initial tumor site in the right frontal lobe, as well as to 25Gy in five
fractions and 18Gy in one fraction in new right temporal and right
cerebellar sites, and finally to 25Gy at the fronto-parietal region
for a marginal recurrence several years later. A complete list of
patient characteristics can be seen on Table 1.
Survival
The median OS from the date of recurrence for all patients was
8months (2.5–61) and the median survival from end of fSRT
treatment was 5.3months (0.6–58). The OS of all patients at 3, 6,
9, 12, 24, 36, and 48months was 74, 47, 32, 26, 13, 13, and 13%,
respectively (Figure 1). Three of the 19 patients, who are described
inmore detail in the discussion, are alive at the time of this review.
Univariate Cox regression model for survival analysis revealed
patients with a frontal lobe tumor (P= 0.05), treatment with
chemotherapy (P= 0.03), treatment with BEV (P= 0.03), an
RPA <5 (P= 0.01), smaller CTVs (P= 0.004), a longer inter-
val between initial diagnosis and recurrence (P= 0.007), or an
TABLE 1 | Patient characteristics.
Patient characteristics
Number of patients 19
Median age 55 (28–78)
Males 13 (68%)
Females 6 (32%)
ECOG 0–1 15 (79%)
ECOG 2+ 4 (21%)
RPA <5 9 (47%)
RPA 5 10 (53%)
Median time to recurrence in mo (range) 16 (2–122)
Mean survival from EoT in mo (range) 11.8 (0.6–58)
Median follow-up in mo 5.3 (0.6–58)
Location
Frontal 9 (47%)
Temporal 6 (32%)
Parietal 2 (10.5%)
Occipital 2 (10.5%)
Initial treatment
Total resection 7 (37%)
Subtotal resection 8 (32%)
Resection (unknown) 4 (21%)
Conventional RT 19 (100%)
Median initial dose in Gy (range) 60 (54–60)
Systemic therapy 19 (100%)
Recurrence treatment
Surgery 3
Systemic therapy 14
Temozolomide 7 (2 before RT, 5 after)
Bevacizumab 9 (3 before RT, 6 after RT)
125 I-mAb 425 6 (3 before RT, 3 after RT)
CyberKnife
Mean CTV in cc (range) 3540 (0.9–151.7)
Mean dose (range) 254 (18–35)
Mean dose per fraction (range) 5.31.3 (4–10)
ECOG, Eastern Cooperative Oncology Group Performance Status; RPA, recursive par-
titioning analysis for glioblastoma multiforme; mo, months; RT, radiotherapy; Gy, Gray;
CTV, clinical target volume; EoT, end of treatment.
Eastern Cooperative Oncology Group (ECOG) performance sta-
tus <1 (P= 0.002) were associated with better survival. Hazard
ratios of the aforementioned prognostic factors range from 2.78
(non-frontally located tumor) to 11.8 (ECOG PF >1), all of
which are shown in Table 2. Kaplan–Meier regression curves
for significant factors are shown in Figures 2–9. KM survival
estimates revealed some differences between particular subgroups
in mean survival from the end of salvage treatment. Those
whose initial tumor recurred after 16months had a survival
of 10.2months compared to 4.7months (P= 0.007) for tumors
recurring sooner. Patients with tumors less than 36 cc survived
8.6months and those with tumors greater than 36 cc survived
2.6months (P= 0.001). Additionally, mean survival was greater
for patients with frontal tumors (8months) compared to non-
frontal tumors (3.3months, P= 0.04) and for those who had
salvage chemotherapy (8.6months) as opposed to those without
it (4.9months, P= 0.02).
Toxicity was not assessed in this study because of the difficulty
in attributing neurocognitive decline to either treatment or
cancer progression, especially retrospectively. However, there
was no evidence of radionecrosis for any patient following fSRT,
nor were any focal deficits noted. Lower grade toxicities such as
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FIGURE 1 | Survival plot for all patients. EOT SRS, end of treatment with stereotactic radiosurgery.
TABLE 2 | Univariate Cox regression models for overall survival.
Variable P-value Hazard ratio
Non-frontal tumor 0.05 2.78 (0.99–7.81)
No systemic therapy 0.03 3.93 (1.16–13.32)
No bevacizumab 0.03 3.31 (1.15–9.58)
RPA 5 0.008 5.78 (1.57–21.28)
Time to recurrence <16monthsa 0.02 5.69 (1.31–24.81)
ECOG >1 0.002 11.8 (2.54–55.16)
CTV >36 ccb 0.004 6.28 (1.80–21.9)
Age >60 0.42 2.19 (0.81–5.94)
RPA, recursive partitioning analysis for glioblastoma multiforme; ECOG, Eastern Cooper-
ative Oncology Group Performance Status; CTV, clinical target volume.
Bold indicates statistical significance.
aMedian value.
bMean value.
nausea/vomiting and headache were noted, but not consistently
documented.
Discussion
Survival
Despite resection being the standard of care for recurrent GBM,
median survivals are between 3 and 13months (40–45), a range
comparable to results with radiosurgery. Additionally, several
surgical series resulted in negative or insignificant survival dif-
ferences when compared to patients without reoperation, and
up to 40% of patients deteriorated within 3months following
surgery (44, 46). Ideal surgical candidates, those surviving over
10months, were similar to the long-term survivors in our study:
under 60 years old with an ECOG of 0 or 1 and a period of at least
6months to recurrence (6). Gorlia and Carson et al. examined a
pooled group of recurrent GBM patients enrolled in prospective
studies receiving conventional chemoradiation with or without
surgery, and revealed even more analogous prognostic factors,
including prior chemotherapy, frontal tumor location, and tumors
less than 50 cc (47, 48).
Retrospective studies similar to this one exhibit 1-year OS rates
ranging from 15 (26) to 45% (27) [median 28%, (30)] for recurrent
GBM treated with SRS/fSRT, with the wide range most likely
attributable to selection bias (Table 3). Two prospective studies,
conducted by Larson et al. (28) and Greenspoon et al. (39), had
median OSs of 9.5 and 9months, respectively. Larson’s study
included 14 GBM patients who received concurrent chemother-
apy and a single fraction of gamma knife SRS prescribed between
the 30–40% isodose line, resulting in a median minimal tumor
dose of 15Gy and a median maximum tumor dose of 50Gy.
Greenspoon evaluated 31 patients in which 95% of the PTV
received 25–35Gy in five fractions with concurrent TMZ. The
latter study only identified tumor size (<3 cm) as a prognosticator
for survival. Greenspoon et al. also reported a grade 3 radiation
necrosis rate of 10%, all responsive to steroids and one patient with
grade 4 toxicity, responsive to anti-angiogenic therapy.
Among the retrospective studies, doses as low as 6Gy
per fraction (37) and as potent as 20Gy in a single fraction
were delivered (26). Normalizing for BED yielded a range of
41.6–75.6Gy among the various studies, of which higher doses
were not associated with longer survival, nor did they report a
higher toxicity rate. Upon multivariate and univariate analyses,
the most consistent prognostic factor was tumor size (27, 37,
39, 49, 50), with the cutoff volume ranging from 10 cc (27) to
30 cc (37), median 24 cc (50). Youth and performance status
were noted as prognostic factors in a few studies (26, 27, 51),
while time interval to recurrence, dose, or chemotherapy use
were not typically associated with a change in outcome. Our data
also suggest that tumor size may be a positive prognosticator,
specifically with CTV less than 36 cc, as well as RPA <5. Unlike
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FIGURE 2 |Months of freedom of death from EOT fSRT by frontal location. Solid line, frontally located tumor; dotted line, non-frontally located tumor; EOT,
end of treatment; fSRT, fractionated stereotactic radiotherapy.
FIGURE 3 |Months of freedom of death from EOT fSRT by chemo. Solid line, patients without systonic therapy; dotted line, patients with systemic therapy;
EOT, end of treatment; fSRT, fractionated stereotactic radiotherapy.
most of the retrospective series, our results also demonstrated
an improvement in survival for tumors located in the frontal
region, use of systemic therapy, or longer interval from diagnosis
to recurrence of greater than 16months, but not with age.
Patients with Long-Term Survival
Three of 19 patients, all males, were alive at last follow-up, who
were 58, 55, and 37 years old at diagnosis of recurrence. The
first patient was originally diagnosed at age 49 with a grade
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FIGURE 4 |Months of freedom of death from EOT fSRT by bevacizumab use. Solid line, patients without bevacizumab; dotted line, patients with
bevacizumab; EOT, end of treatment; fSRT, fractionated stereotactic radiotherapy.
FIGURE 5 |Months of freedom of death from EOT fSRT by RPA. Solid line, patients with recursive partitioning analysis less than 5; dotted line, patients with
recursive partitioning analysis greater than or equal to 5; EOT, end of treatment; fSRT, fractionated stereotactic radiotherapy.
2 astrocytoma in the right frontal lobe, which was completely
resected, irradiated to 54Gy with standard fractionation, and
recurred as a GBM 10 years later manifesting with left-sided
weakness. The 3.2 cm lesion was excised, six Gliadel wafers were
implanted in its location. However, treatment-planning MRI
2months postoperatively revealed enhancement in the surgically
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FIGURE 6 |Months of freedom of death from EOT fSRT by age of recurrence. Solid line, less than or equal to 60 years old; dotted line, greater than or equal to
60 years old; EOT, end of treatment; fSRT, fractionated stereotactic radiotherapy.
FIGURE 7 |Months of freedom of death from EOT fSRT by performance status. Solid line, Eastern Cooperative Oncology Group Performance Status less
than or equal to 1; dotted line, Eastern Cooperative Oncology Group Performance Status greater than 1; EOT, end of treatment; fSRT, fractionated stereotactic
radiotherapy.
resected area, as well as new enhancement in the right temporal
lobe and right cerebellumwithCTV’s of 5.9, 0.7, and 0.6 cc, respec-
tively. Consequently, in a span of 3weeks, the original tumor
bed was re-irradiated to 20Gy in five fractions, temporal lesion
irradiated to 25Gy in five fractions, and the cerebellar recur-
rence received 18Gy in a single fraction with dose fractionation
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FIGURE 8 |Months of freedom of death from EOT fSRT by clinical target volume. Solid line, clinical target volume less than or equal to 36 cc; dotted line,
clinical target volume greater than 36 cc; EOT, end of treatment; fSRT, fractionated stereotactic radiotherapy.
FIGURE 9 |Months of freedom of death from EOT fSRT by time to recurrence. Solid line, recurrence less than or equal to 16months since initial diagnosis;
dotted line, recurrence greater than 16months since initial diagnosis; EOT, end of treatment; fSRT, fractionated stereotactic.
chosen after review of prior external radiation dose to each site.
Three weeks following radiation, the patient had increased mild
left-sided weakness that slowly subsided. He had no evidence of
disease for almost 4 years, until his performance status declined
with frequent falls secondary to left lower extremity weakness. An
MRI showed an enhancing lesion posterior to the original tumor,
Frontiers in Oncology | www.frontiersin.org May 2015 | Volume 5 | Article 1068
Hasan et al. fSRT for GMB recurrence
TABLE 3 | Review of the literature.
Reference N Med. dose
(range)
No. of
Fx
Median
BED
Med. size
(range)
ReOp
rate
Systemic therapy
rate
Med. OS from
RT (mo)
1-Year
OS (%)
2-Year
OS (%)
Combs et al. (30) 32 15 1 63.75 10 0 – 7 28 –
Patel et al. (34) 26 18 (12–20) 1 75.6 10 (1–60) 11 – 8.4 – –
Lederman et al. (37) 88 24 4 43.2 33 (2–50) 12 – 7 17 3.4
Hall et al. (26) 26 20 1 – 28 31 – 7.5 15 0
Shrieve et al. (27) 86 13 (6–20) 1 41.6 10 (2–83) – – 10.2 45 19
Mahajan et al. (31) 41 – 1 – 5 (1–16) – – 11 29 –
Kong et al. (49) 65 16 1 60.8 – – 49 13 20.5 –
Larson et al. (28) 14a 12–20 1 – 8 (2–30) – 100 9.5 – –
Yazici et al. (50) 37 30 (14–32) 1–5 48 24 (2–81) – – 10.6 – –
Martinez et al. (51) 46 18 (14–20) 1 75.6 6 43 – 7.5 40 16
Greenspoon et al. (39) 31a 25–35 5 40–56 12 0 100 9 – –
Current study 19 25 (18–30) 5 40 24 21 74 5.3 26 13
N, number of patients; Med, median; No. of Fx, number of fractions; BED, biological equivalent dose; ReOp, reoperation; OS, overall survival; RT, radiotherapy; Mo, months;
%, percentage.
aProspective study.
which was once again re-irradiated to 25Gy in five fractions,
resulting in improved motor function of the symptomatic lower
extremity. In total, the patient received five separate radiation
treatments, four of which were CyberKnife treatments for recur-
rence. Upon completion of the most recent course of fSRT, the
patient completed 12 cycles of BEV with stable disease off any
chemotherapy. Although his latest KPS is 50, he is currently alive
with no evidence of recurrence at 63 years of age, 4 years and
9months following initial fSRT.
The second living patient was diagnosed at age 48 with GBM of
the left frontal lobewhichwas completely resected. The patient did
not receive postoperative chemoradiation, however he remained
free of disease for 5 years. His recurrence was discovered by
a follow-up MRI in the left fronto-parietal lobe and was once
again resected, this time subtotally. He also received external
beam radiation to 60Gy in 30 fractions to the tumor bed with
TMZ. Clinically, the patient had a KPS of 80 with stable right-
sided upper and lower extremity weakness and mild motor apha-
sia, which began when his original tumor was discovered. The
patient was maintained on TMZ followed by BEV for 30months
after recurrence until his right-sided weakness became progres-
sively worse, especially in the lower extremity, leading to fre-
quent falls. An MRI showed obvious progression of disease in
the left frontal lobe and the patient elected CyberKnife to treat
the 9.5 cc lesion with 25Gy in five fractions. He again received
BEV which was stopped over a year ago due to decline in renal
function. For over 4 years since fSRT re-irradiation, the patient
has shown no evidence of disease progression and although he
has a baseline left-sided hemiparesis and mild aphasia, physi-
cal and speech therapy has slowly improved those neurological
deficits.
The last patient alive at last follow-up was 37 years old when
he was originally diagnosed with a frontal butterfly GBM that
was subtotally resected followed by 60Gy of standard external
beam radiation and TMZ. He was subsequently given BEV and
showed no signs of recurrence until anMRI 2.5 years later showed
an increased mass in the genu and rostrum of the corpus callo-
sum. The recurrence was again subtotally resected and adjuvant
treatment included 25Gy in five fractions fSRT re-irradiationwith
CyberKnife to a suspicious 27.3 cc area near the corpus callosum.
Following fSRT, he has been maintained on BEV and irinotecan.
At last follow-up, 20months have passed since completion of
fSRT with no evidence of recurrence. Since he was originally
diagnosed, the patient has been neurologically asymptomatic with
the exception of headaches.
Limitations
This study is limited by an inherent selection bias given its retro-
spective nature. The population is relatively heterogeneous with
regard to prior treatment and patient characteristics, although not
unlike similar studies in the literature.While the data are powered
enough for a univariate Cox regression model, a patient popula-
tion of 19 precludes any type of multivariate analysis. Therefore,
the calculated hazard ratios may not reflect the true impact of
an associated prognostic factor as covariance likely exists among
the variables. However, independent interpretation of a given
prognosticator with a significant hazard ratio suggests an effect
on survival assuming all other variables are equal.
Conclusion
Although an improved survival with chemoradiation for inop-
erable primary GMB patients has been reported, the treatment
paradigm for recurrence has not been as clear. However, sev-
eral studies including this one have demonstrated that SRS/fSRT
can be delivered as salvage re-irradiation safely, with survival
outcomes comparable to those historically treated with reoper-
ation or chemotherapy alone (6, 11). Furthermore, there may
be select patients, particularly those with smaller tumors or
good performance status who could potentially benefit from re-
irradiation. Our study documents several patients who lived years
after re-irradiation via CyberKnife fSRT for recurrent tumors,
with favorable prognosticators including frontal lobe location,
tumor volume less than 36 cc, use of systemic therapy, or an
RPA <5. Confounding variables make it difficult to accurately
measure the true impact of such factors on survival, but the data
might help provide a starting point for patient selection. Addition-
ally, tumor biology unaccounted for in this experience may also
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impact survival, such as the presence of radioresistant biomarkers
like SYK, STAT3, and SKY pathway genes. In order to investigate
which recurrent GBM patients will truly benefit from fSRT/SRS,
prospective trials evaluating survival, local control, prognostic
factors, and toxicity should be conducted. In the absence of ran-
domized evidence, it remains unknown if radiosurgery improves
OS in recurrent GBM, nevertheless it can safely and often times
effectively be used as salvage therapy, particularly in conjunction
with chemotherapy. Radiation Therapy Oncology Group (RTOG)
1205 should offer valuable insight regarding the efficacy of re-
irradiation and BEV vs. BEV alone for recurrent GBM. Although
the radiation dose in the phase II trial requires 35Gy in 10 frac-
tions, which is not considered SRS/fSRT, it may open the door for
such prospective trials in the future.
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